Latham BioPharm Group

What Latham BioPharm Group does

Latham BioPharm Group (LBG) is a US-based life sciences consulting firm founded in 1996 by Peter Latham and headquartered in Frederick, Maryland. The firm provides three core service lines: non-dilutive funding advisory (helping clients secure and manage government and NGO grants from agencies such as BARDA, NIH, and DoD), product development consulting (CMC, regulatory, clinical, nonclinical, discovery, quality, and project management for vaccines, therapeutics, cell and gene therapies, medical devices, diagnostics, and animal health products), and strategic consulting (market research, financial modeling, due diligence, market access, and technology scouting). LBG operates across four sector specializations—LBG Biologics, LBG Pharma, LBG MD&D (Medical Devices, Diagnostics, and Digital Health), and LBG Animal Health—with a team of approximately 60 life sciences consultants.

LBG's revenue model is professional services fee-based, with consulting engagements quoted per project and not publicly disclosed. Clients span US government agencies (BARDA, NIH, DoD components including CDMRP, DARPA, and DTRA), large NGOs and foundations (Bill & Melinda Gates Foundation, CEPI), and commercial pharmaceutical, biotech, medical device, and animal health companies. In October 2022, LBG was acquired by Sia Partners, a global consulting firm, and now operates as Sia's Life Science Consulting division; founder Peter Latham heads the global Life Science division on Sia's Executive Committee. The firm's most notable recent product expansion is the Global Health Cost Model Platform, a web-based pharmaceutical API cost-of-goods modeling tool developed with Bill & Melinda Gates Foundation grant funding.

Name

Latham BioPharm Group

Legal name

Latham BioPharm Group

Website

https://lathambiopharm.com

Company type

Private

Founded year

1996

Operating status

Operating

Headcount range

51–100 employees

Short description

Latham BioPharm Group is a US life sciences consulting firm providing non-dilutive funding advisory, product development consulting, and strategic consulting services to government agencies, NGOs, and pharmaceutical, biotech, medical device, and animal health companies with a team of approximately 60 consultants.

Ownership category

akta.pro rank

Product category

Life Sciences Consulting

NAICS

Other Scientific and Technical Consulting Services (54169), Management, Scientific, and Technical Consulting Services (5416)

SIC

Services-Management Consulting Services (8742), Services-Commercial Physical & Biological Research (8731)

akta.pro industry

PRIMARYHLAGAKAJ

Manufacturing Quality Assurance & GMP Compliance (batch release, deviation/CAPA, tech transfer QA)

Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Regulatory Affairs, Quality & Compliance Services (GxP)

SECONDARYHLAGAKAL

Quality Engineering & Risk Management (ICH Q9/Q10, validation, change control)

Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Regulatory Affairs, Quality & Compliance Services (GxP)

Keywords

• Life sciences consulting
• Non-dilutive funding
• Biopharmaceutical strategy
• Product development consulting
• Government contract advisory

Headquarters

HQ city

Elkridge

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Marketing or Sales, Technology or R&D, Infrastructure

Revenue model

1. Life Sciences Consulting Services: Professional consulting services including non-dilutive funding support, product development consulting, and strategic consulting. Turnover of nearly $20m as of acquisition in 2022.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels5 records

Core offering

Latham BioPharm Group (LBG) provides life sciences consulting services across three core service areas: Non-dilutive Funding Services (government relations, proposal development, post-award support, contract compliance), Product Development Services (CMC, Regulatory, Clinical, Nonclinical, Discovery, Quality, Project Management, Vendor Management), and Strategic Consulting Services (strategic planning, financial modeling, market research, supply chain optimization, market access, due diligence, technology scouting). The firm supports pharma, biotech, medical device, diagnostic, animal health, and government clients with a team of nearly 60 consultants.

Product overview

Latham BioPharm Group (LBG) provides life sciences consulting services organized into three core service areas: Non-dilutive Funding Services (government relations, proposal development, post-award support, contract compliance), Product Development Services (CMC, Regulatory, Clinical, Nonclinical, Discovery, Quality, Project Management, Vendor Management), and Strategic Consulting Services (Strategic Planning, Financial Modeling, Market Research, Supply Chain Optimization, Market Access/Launch, Due Diligence, Technology Scouting). The company operates across four sector specializations: LBG Biologics, LBG Animal Health, LBG Pharma, and LBG MD&D (Medical Devices, Diagnostics, and Digital Health). In 2023, LBG launched the Global Health Cost Model Platform, a web-based tool for pharmaceutical API cost analysis developed with Bill & Melinda Gates Foundation funding.

Differentiator

Problem solved

Functional benefit

Products and services

• Non-dilutive Funding Services Consulting services to help life sciences clients secure government and non-governmental funding, including government relations, proposal development, post-award support, and contract compliance. Targets biotech, pharma, and academic organizations seeking non-dilutive funding sources such as BARDA, NIH, and DoD.
• Product Development Services Comprehensive product development support including CMC (Chemistry, Manufacturing, and Controls), Regulatory, Clinical, Nonclinical, Discovery, Quality, Project Management, and Vendor Management services for vaccines, therapeutics, cell and gene therapies, medical devices, and diagnostics.
• Strategic Consulting Services Consulting services including Strategic Planning, Financial Modeling, Market Research, Supply Chain Network Development & Optimization, Market Access/Launch, Due Diligence, and Technology Scouting for life sciences companies.
• Global Health Cost Model Platform A web-based modeling tool for determining the cost of goods of pharmaceutical APIs (Active Pharmaceutical Ingredients), enabling stakeholders to evaluate the viability and manufacturing approaches of pharmaceutical products for global health access.

Quantifiable outcome

• Led submission of proposals resulting in $400 million in awards
• +3 more outcomes

Named customers5 records

Segments4 records

Ideal customer profiles4 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature1 record

Partnerships

Eight partnerships are on record, tiered core and minor.

• Bill & Melinda Gates FoundationcoreStrategic or Co-development Partner · 21 June 2023LBG awarded a grant to develop a web-based modeling tool for calculating pharmaceutical API costs. The tool aims to help stakeholders evaluate the economic viability of pharmaceutical products and manufacturing approaches, supporting global health access.
• Sia PartnerscoreStrategic or Co-development Partner · 14 October 2022Sia Partners acquired Latham BioPharm Group in October 2022, creating a Life Science Consulting division. The acquisition accelerates Sia Partners' growth in the life sciences sector. LBG founder Peter Latham heads the new global Life Science division within Sia Partners' ExCom.
• Alliance for Regenerative Medicine (ARM)minorStrategic or Co-development Partner · 1 August 2022Jim Beltzer contributed to Project A-Cell, a multistakeholder collaboration incorporating Quality by Design principles into CAR-T therapy manufacturing, bringing CMC best practices to cell-based therapy field.
• National Institute for Innovation in Manufacturing Biopharmaceuticals (NIIMBL)minorStrategic or Co-development Partner · 1 August 2022Partnered with NIIMBL on Project A-Cell, contributing expertise to standardize manufacturing methodologies for cell-based therapies.
• Biomedical Advanced Research and Development Authority (BARDA)coreStrategic or Co-development PartnerLBG supports clients in securing and managing BARDA contracts. Notable example: Joseph Rininger led a $147 million BARDA contract for Flublok vaccine development.
• BioPharm InternationalminorGTM or Marketing PartnerLBG team members regularly publish articles in BioPharm International magazine on regulatory compliance, FDA 483 observations, and pharmaceutical quality topics.
• New York University (NYU)minorStrategic or Co-development PartnerCollaborating with NYU on Smart Diagnostics projects incorporating AI to improve accuracy and clinical utilization of diagnostic tools.
• American Association for Clinical Chemistry (AACC)minorGTM or Marketing PartnerLBG team members attend and network at AACC Annual Scientific Meeting to engage with the global laboratory medicine community.

Scale indicators9 records

Recent moves6 records

Expansion highlights5 records

Direct peers

• ClearView Healthcare Partners: Life sciences strategy consulting firm providing commercial, R&D, and corporate strategy support to biopharma, similar in size and specialty positioning to LBG.
• Trinity Life Sciences: Strategic consulting firm serving pharma and biotech with therapeutic-area strategy, market research, and product development advisory, directly comparable to LBG's strategic consulting and product development practices.
• Putnam Associates: Life sciences-focused consulting firm offering strategic, market access, and product development advisory to pharma/biotech, overlapping directly with LBG's strategic consulting and product development offerings.
• Health Advances: Healthcare and life sciences strategy consulting firm supporting medtech, diagnostics, and biotech clients with commercialization and product development strategy, a closely matched peer in scale and scope.
• Back Bay Life Science Advisors: Boutique life sciences consulting firm providing strategy, market assessment, and product development advisory to biotech and pharma, a close peer in size and specialty orientation to LBG.

Broad incumbents

• ZS Associates: Large global consulting firm with deep pharma/biotech practice spanning strategy, R&D, and commercial, an established incumbent that competes with LBG for pharma advisory engagements.
• LEK Consulting (Life Sciences): Global strategy consulting firm with a sizable life sciences practice offering commercial, R&D, and transaction advisory to pharma and biotech, competing for similar strategic consulting mandates as LBG.
• Charles River Associates (Life Sciences Practice): Global consulting firm with a dedicated Life Sciences practice providing economic, strategic, and regulatory consulting to biopharma, overlapping with LBG on regulatory and strategic work but operating at much larger scale.
• IQVIA (Consulting & Services): Global life sciences services and consulting powerhouse covering R&D strategy, regulatory, and commercial advisory, an incumbent that competes with LBG particularly for CMC, regulatory, and strategic consulting work.
• Parexel International (Consulting): Global CRO with regulatory and product development consulting capabilities that overlap with LBG's CMC and regulatory advisory work, particularly for biotech and government-funded programs.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks5 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/2203757

Revenue estimate

Valuation estimate

Number of profiles

Profiles11 records

Funding overview

Funding rounds3 records

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Latham BioPharm Group